ASCO: Teclistamab Improves Survival in Relapsed, Refractory Multiple Myeloma

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on June 2, 2026.

via HealthDay

TUESDAY, June 2, 2026 -- For patients with relapsed or refractory multiple myeloma, teclistamab monotherapy significantly improves progression-free and overall survival, according to a study published online May 29 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 29 to June 2 in Chicago.

Cyrille Touzeau, M.D., Ph.D., from the University Hospital of Nantes in France, and colleagues randomly assigned patients with relapsed or refractory multiple myeloma who had previously received one, two, or three lines of therapy, including an anti-CD38 monoclonal antibody and lenalidomide, to receive teclistamab (296 patients) or the investigator's choice of pomalidomide, bortezomib, and dexamethasone (PVd) or carfilzomib and dexamethasone (Kd; 297 patients).

The researchers found that teclistamab significantly improved progression-free survival versus PVd or Kd (estimated 18-month progression-free survival, 69.8 versus 26.9 percent; hazard ratio for disease progression or death, 0.29). Compared with PVd or Kd, the percentage of patients with a complete response or better was higher with teclistamab (65.9 versus 16.8 percent). Compared with PVd or Kd, overall survival was improved with teclistamab (estimated 18-month overall survival, 79.2 versus 68.6 percent; hazard ratio for death, 0.60). Adverse events of grade 3 or 4 occurred in 84.9 and 76.3 percent of teclistamab and PVd or Kd recipients, respectively; grade 5 adverse events occurred in 6.5 and 3.5 percent, respectively.

"To see that this drug is so efficacious and so safe across patients from all these locations worldwide is a very strong signal," senior author C. Ola Landgren, M.D., Ph.D., from the University of Miami, said in a statement.

Several authors disclosed ties to biopharmaceutical companies, including Johnson & Johnson, which manufactures teclistamab and funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-06-03 03:42

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords